Please login to the form below

Not currently logged in
Email:
Password:

Lilly elects Prof Carolyn Bertozzi to board of directors

She brings oncology, inflammation and infection research expertise to the firm

Eli Lilly has elected Prof Carolyn Bertozzi to its board of directors, where she will serve as a member of the science and technology, public policy and compliance committees.

Prof Bertozzi is currently the Anne T and Robert M Bass professor of chemistry and professor of chemistry and systems biology and radiology at Standford University, and serves as an investigator at the Howard Hughes Medical Institute.

She first joined Stanford in 2015 with the launch of its ChEM-H Institute, having previously been a member of the UC Berkley College of Chemistry.

Her research focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection to develop diagnostic and therapeutic approaches.

Prof Bertozzi is a member of the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences.

Dr John Lechleiter, chairman of Eli Lilly's board of directors, said: “We are very pleased to welcome Carolyn Bertozzi to the Lilly board.

“Professor Bertozzi, with her broad scientific expertise and solid record of accomplishment, along with her understanding of the biopharmaceutical industry, will contribute greatly to our board and our company as we seek to advance Lilly's pipeline of potential new medicines to benefit patients and our other key stakeholders.”

17th February 2017

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics